✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyIndustry Why This Matters Sonas Pharma’s funding advancement for endocannabinoid-based therapeutics is clinically relevant because...
What to know about how GLP-1 medications might fight addiction – The Washington Post
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyNeurology Why This Matters GLP-1 medications may offer clinicians a novel pharmacological option for...
Daily Digest: Last 19 Hours: Aging Brains, Adolescent Risk, and the Slow March of Policy Reform — March 04, 2026
A synthesis of 53 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
West Virginia House approves bill allowing medical cannabis edibles | WV News
WHY IT MATTERS: West Virginia medical cannabis patients who previously had limited delivery options may soon be able to access edible formulations, giving physicians and patients more tools to tailor treatment to individual medical needs. CLINICAL OVERVIEW: West Virginia’s expansion of its medical cannabis program to include edible formulations represents a meaningful step toward improving patient access and treatment flexibility. Edibles offer distinct pharmacokinetic advantages for certain patient populations, particularly those with respiratory conditions who cannot tolerate inhalation, or those requiring longer-duration symptom relief due to the slower onset and extended duration of orally administered cannabinoids.
Ananda Pharma to Begin Dosing in NHS-Backed CBD Endometriosis Trial
WHY IT MATTERS: Women with endometriosis who are considering CBD as part of their pain management may soon have access to NHS-level clinical trial data to inform conversations with their physicians about safety and dosing. CLINICAL OVERVIEW: Endometriosis affects roughly one in ten women of reproductive age and remains chronically undertreated, with many patients cycling through years of hormonal therapies and surgical interventions before achieving meaningful relief. CBD has emerged as a candidate for managing the chronic pelvic pain and inflammatory burden associated with endometriosis, partly through its interactions with the endocannabinoid system, which is increasingly understood to play a role in uterine function and pain signaling.
High Tide joins U.S. National Compassionate Care Council | HITI Stock News
WHY IT MATTERS: Patients relying on medical cannabis for serious conditions may see improved access, more consistent product standards, and stronger legal protections if compassionate care policy reforms move forward at the federal level. CLINICAL OVERVIEW: Efforts to modernize medical cannabis policy at a national level reflect a growing recognition that patients deserve structured, evidence-informed access to cannabinoid therapies rather than navigating a fragmented and inconsistent regulatory landscape. Compassionate care frameworks have historically served as critical pathways for patients with serious or treatment-resistant conditions to access medications outside of standard channels.
A Prescription Digital Therapeutic Framework for Enhancing Medical Cannabis Care
WHY IT MATTERS: Patients using medical cannabis may soon have access to digital tools that help their physicians track symptom changes and adjust treatment more precisely over time. CLINICAL OVERVIEW: The integration of prescription digital therapeutics into cannabinoid medicine represents a meaningful step toward structuring clinical care around measurable outcomes, individualized dosing protocols, and accountable therapeutic frameworks. Digital tools have the potential to capture real-world patient data that traditional clinical encounters often miss, including symptom trajectories, titration responses, and adherence patterns.
Cannabis Use and Brain Aging: What a Major Study Reveals – Born2Invest
WHY IT MATTERS: Patients who use cannabis regularly and are concerned about long-term brain health now have large-scale data to discuss with their physician, though the findings underscore the importance of individualized conversations rather than blanket reassurance or alarm. CLINICAL OVERVIEW: Research drawing on large biobank datasets has examined whether cannabis use is associated with measurable changes in brain aging trajectories. The findings suggest a nuanced picture in which cannabis users may show some initial differences in brain age metrics, but the relationship between cannabis exposure and long-term neurological aging is not straightforwardly harmful or protective.
Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online
WHY IT MATTERS: Patients who use cannabis heavily should know that research is actively examining how cannabis use disorder compares to other substance use disorders in terms of real-world psychiatric risks, which may affect how clinicians screen and counsel them going forward. CLINICAL OVERVIEW: Research comparing cannabis use disorder to other substance use disorders is an important area of inquiry because it helps clinicians understand the relative psychiatric burden associated with problematic cannabis use in the context of a rapidly changing legal and cultural landscape. Propensity-score-matched study designs are valuable here because they attempt to control for the many confounding variables that make substance use populations inherently difficult to compare fairly.
Endocannabinoid System Research: Cannabis & Autism Risk
Clinical Takeaway Children exposed to cannabis during the peripregnancy period showed associations with behavioral and developmental differences in offspring, with effects varying based on whether children had ASD symptoms. These findings suggest...